Asymmetric dimethylarginine (ADMA) has a role in regulating systemic vascular tone in young healthy subjects: the cardiovascular risk in young Finns study.
BACKGROUND
This study was designed to evaluate whether plasma asymmetric dimethylarginine (ADMA) has any role in predicting hemodynamic responses in clinically healthy young subjects. ADMA, as an endogenous nitric oxide (NO) synthase inhibitor, has been demonstrated to associate with hypertension and vascular reactivity in experimental but not undoubtedly in physiological settings.


METHODS
A total of 199 subjects aged 31.4 years (range 24-39 years) were studied. Plasma ADMA and symmetric dimethylarginine (SDMA) were assessed by isocratic high-pressure liquid chromatography using precolumn derivatization with o-phtaldialdehyde at baseline. Blood pressure (BP) was measured by casual measurements in the beginning of the study and after a follow-up period of 2.45 +/- 0.42 years (range, 1.86-3.19 years). Hemodynamic regulation was assessed by noninvasive methods after a follow-up.


RESULTS
Plasma ADMA had a negative association with resting systemic vascular resistance index (SVRI) (r = -0.23, P < 0.01) and pulse wave velocity (PWV) (r = -0.17, P < 0.05) and positive association with cardiac index (CI) (r = 0.21, P < 0.01) after the follow-up. Plasma ADMA had also negative association with responses of SVRI (r = -0.19, P < 0.01) and positive association with CI (r = 0.25, P < 0.001) in a hemodynamic reactivity test. In a multivariate linear model (R2 = 0.20, P < 0.00001), diastolic BP (R = 0.37, P < 0.00001) and ADMA (R = -0.20, P < 0.01) were significant predictors of SVRI.


CONCLUSIONS
These results suggest that plasma ADMA seems to play a role in the regulation of vascular tone in young healthy subjects.
Emergency Department, University Hospital of Tampere, Tampere, Finland. hannu.paiva@pshp.fi
Hannu
H
Päivä
Mika
M
Kähönen
Terho
T
Lehtimäki
Olli T
OT
Raitakari
Antti
A
Jula
Jorma
J
Viikari
Georg
G
Alfthan
Markus
M
Juonala
Reijo
R
Laaksonen
Nina
N
Hutri-Kähönen
D000328:Adult; D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D001794:Blood Pressure / Q000502:physiology*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D007668:Kidney / Q000502:physiology; D008055:Lipids / Q000097:blood; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D012307:Risk Factors; D014655:Vascular Resistance / Q000502:physiology*; D014661:Vasoconstriction / Q000502:physiology*; D055815:Young Adult
D008055:Lipids; D009569:Nitric Oxide; C018524:N,N-dimethylarginine; D001120:Arginine